kezar life sciences pipeline

Kezar has a market capitalization of 25441 million on a stock price of 544 which is slightly below the midpoint of the 52-week range of 218 to 979. Its product pipeline include KZR-616 KZR-261.

Kezar Life Sciences Establishing New Paths For Treating Chronic Disease

KZR shares are soaring Tuesday following a positive clinical readout.

. In addition Kezar is reporting an unaudited cash position of approximately 307 million including cash cash equivalents and marketable securities as of June 30 2022. Kezars pipeline consists of three investigational compounds. Kezar Life Sciences corporate presentation Kezar has reported phase 1 data for KZR-616 in LN PM and DM and is currently.

Kezar Life Sciences pipeline Source. KZR a clinical-stage biotechnology company discovering and developing breakthrough treatments for. Complete Kezar Life Sciences Inc.

View real-time KZR stock price and news along with industry-best analysis. Kezar Life Sciences Inc. Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.

Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Kezar Life Sciences. Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update. Kezars complementary therapeutic platforms harness key regulators of cellular function and inhibit multiple drivers of disease enabling the potential for significant clinical.

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. July 15 2021 at 1100 AM EDT. SOUTH SAN FRANCISCO Calif October 06 2022--Kezar Life Sciences Inc Nasdaq.

Stock information by Barrons. William Blair Biotech Focus Conference 2021. August 11 2022 at 401 PM EDT.

The Investor Relations website contains information about Kezar Life Sciences Incs business for stockholders potential investors and financial analysts. Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. September 1 2022 at 700 AM EDT.

Kezar Life Sciences Targeting The Immunoproteasome To Treat Autoimmunity Nasdaq Kzr Seeking Alpha